nodes	percent_of_prediction	percent_of_DWPC	metapath
Budesonide—Amcinonide—ANXA1—esophageal cancer	0.0128	0.278	CrCbGaD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—KRT17—esophageal cancer	0.00737	0.0506	CbGpPWpGaD
Budesonide—Coagulopathy—Capecitabine—esophageal cancer	0.00542	0.00671	CcSEcCtD
Budesonide—Multiple fractures—Methotrexate—esophageal cancer	0.0054	0.00669	CcSEcCtD
Budesonide—Fracture—Methotrexate—esophageal cancer	0.0054	0.00669	CcSEcCtD
Budesonide—Hydrocortisone—ANXA1—esophageal cancer	0.0054	0.117	CrCbGaD
Budesonide—Testolactone—CYP19A1—esophageal cancer	0.00516	0.112	CrCbGaD
Budesonide—Dysphonia—Capecitabine—esophageal cancer	0.00513	0.00635	CcSEcCtD
Budesonide—Contusion—Capecitabine—esophageal cancer	0.00484	0.00598	CcSEcCtD
Budesonide—CYP3A4—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00474	0.0325	CbGpPWpGaD
Budesonide—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00464	0.00574	CcSEcCtD
Budesonide—NR3C1—Nuclear Receptors—NR1I2—esophageal cancer	0.00462	0.0317	CbGpPWpGaD
Budesonide—Herpes simplex—Capecitabine—esophageal cancer	0.00458	0.00567	CcSEcCtD
Budesonide—Nasal congestion—Cisplatin—esophageal cancer	0.00456	0.00564	CcSEcCtD
Budesonide—Nocturia—Capecitabine—esophageal cancer	0.00455	0.00563	CcSEcCtD
Budesonide—Ulcer—Capecitabine—esophageal cancer	0.00446	0.00552	CcSEcCtD
Budesonide—Cataract—Capecitabine—esophageal cancer	0.00443	0.00548	CcSEcCtD
Budesonide—Amnesia—Cisplatin—esophageal cancer	0.00442	0.00547	CcSEcCtD
Budesonide—Neck pain—Capecitabine—esophageal cancer	0.00427	0.00528	CcSEcCtD
Budesonide—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.00422	0.00522	CcSEcCtD
Budesonide—NR3C1—AP-1 transcription factor network—CRTC1—esophageal cancer	0.00409	0.028	CbGpPWpGaD
Budesonide—Candida infection—Capecitabine—esophageal cancer	0.00403	0.00498	CcSEcCtD
Budesonide—Dexamethasone—ANXA1—esophageal cancer	0.00403	0.0874	CrCbGaD
Budesonide—Face oedema—Cisplatin—esophageal cancer	0.00401	0.00496	CcSEcCtD
Budesonide—Fluid retention—Capecitabine—esophageal cancer	0.00401	0.00496	CcSEcCtD
Budesonide—Abscess—Methotrexate—esophageal cancer	0.00397	0.00491	CcSEcCtD
Budesonide—Irritability—Cisplatin—esophageal cancer	0.00397	0.00491	CcSEcCtD
Budesonide—Ecchymosis—Capecitabine—esophageal cancer	0.00381	0.00472	CcSEcCtD
Budesonide—Hypokalaemia—Cisplatin—esophageal cancer	0.00378	0.00468	CcSEcCtD
Budesonide—Breast disorder—Cisplatin—esophageal cancer	0.00375	0.00465	CcSEcCtD
Budesonide—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00375	0.0257	CbGpPWpGaD
Budesonide—Cramp muscle—Cisplatin—esophageal cancer	0.00374	0.00463	CcSEcCtD
Budesonide—Nasopharyngitis—Cisplatin—esophageal cancer	0.00372	0.0046	CcSEcCtD
Budesonide—Abnormal vision—Capecitabine—esophageal cancer	0.00368	0.00455	CcSEcCtD
Budesonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—ALDOB—esophageal cancer	0.00366	0.0251	CbGpPWpGaD
Budesonide—NR3C1—Nuclear Receptor transcription pathway—NR1I2—esophageal cancer	0.00365	0.025	CbGpPWpGaD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—KRT14—esophageal cancer	0.0036	0.0247	CbGpPWpGaD
Budesonide—Ear pain—Capecitabine—esophageal cancer	0.00359	0.00444	CcSEcCtD
Budesonide—Sleep disorder—Capecitabine—esophageal cancer	0.00354	0.00438	CcSEcCtD
Budesonide—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00352	0.00436	CcSEcCtD
Budesonide—Sweating increased—Cisplatin—esophageal cancer	0.0035	0.00433	CcSEcCtD
Budesonide—Bone disorder—Methotrexate—esophageal cancer	0.00348	0.0043	CcSEcCtD
Budesonide—Swelling—Capecitabine—esophageal cancer	0.00347	0.0043	CcSEcCtD
Budesonide—Gastroenteritis—Capecitabine—esophageal cancer	0.00346	0.00428	CcSEcCtD
Budesonide—Vascular purpura—Capecitabine—esophageal cancer	0.00342	0.00424	CcSEcCtD
Budesonide—Herpes simplex—Methotrexate—esophageal cancer	0.00341	0.00422	CcSEcCtD
Budesonide—Glossitis—Methotrexate—esophageal cancer	0.00341	0.00422	CcSEcCtD
Budesonide—Ulcer—Methotrexate—esophageal cancer	0.00332	0.00411	CcSEcCtD
Budesonide—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.0033	0.0226	CbGpPWpGaD
Budesonide—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00328	0.0225	CbGpPWpGaD
Budesonide—Amnesia—Capecitabine—esophageal cancer	0.00326	0.00403	CcSEcCtD
Budesonide—Increased appetite—Capecitabine—esophageal cancer	0.00326	0.00403	CcSEcCtD
Budesonide—Thirst—Capecitabine—esophageal cancer	0.00322	0.00398	CcSEcCtD
Budesonide—Purpura—Capecitabine—esophageal cancer	0.00318	0.00393	CcSEcCtD
Budesonide—Arthritis—Capecitabine—esophageal cancer	0.00315	0.0039	CcSEcCtD
Budesonide—Conjunctivitis—Cisplatin—esophageal cancer	0.00311	0.00385	CcSEcCtD
Budesonide—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00303	0.0208	CbGpPWpGaD
Budesonide—Migraine—Capecitabine—esophageal cancer	0.00301	0.00373	CcSEcCtD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX1—esophageal cancer	0.00296	0.0203	CbGpPWpGaD
Budesonide—Face oedema—Capecitabine—esophageal cancer	0.00296	0.00366	CcSEcCtD
Budesonide—Irritability—Capecitabine—esophageal cancer	0.00292	0.00362	CcSEcCtD
Budesonide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00291	0.02	CbGpPWpGaD
Budesonide—Mood swings—Capecitabine—esophageal cancer	0.0029	0.00359	CcSEcCtD
Budesonide—Ecchymosis—Methotrexate—esophageal cancer	0.00284	0.00351	CcSEcCtD
Budesonide—Urinary tract disorder—Cisplatin—esophageal cancer	0.00284	0.00351	CcSEcCtD
Budesonide—Connective tissue disorder—Cisplatin—esophageal cancer	0.00282	0.0035	CcSEcCtD
Budesonide—Urethral disorder—Cisplatin—esophageal cancer	0.00282	0.00349	CcSEcCtD
Budesonide—Abdominal pain upper—Capecitabine—esophageal cancer	0.0028	0.00346	CcSEcCtD
Budesonide—Hypokalaemia—Capecitabine—esophageal cancer	0.00279	0.00345	CcSEcCtD
Budesonide—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00278	0.0191	CbGpPWpGaD
Budesonide—Visual impairment—Cisplatin—esophageal cancer	0.00277	0.00343	CcSEcCtD
Budesonide—Breast disorder—Capecitabine—esophageal cancer	0.00277	0.00342	CcSEcCtD
Budesonide—Nasopharyngitis—Capecitabine—esophageal cancer	0.00274	0.00339	CcSEcCtD
Budesonide—Eye disorder—Cisplatin—esophageal cancer	0.00269	0.00332	CcSEcCtD
Budesonide—Lymphadenopathy—Methotrexate—esophageal cancer	0.00267	0.00331	CcSEcCtD
Budesonide—Cardiac disorder—Cisplatin—esophageal cancer	0.00267	0.0033	CcSEcCtD
Budesonide—Flushing—Cisplatin—esophageal cancer	0.00267	0.0033	CcSEcCtD
Budesonide—Abdominal distension—Capecitabine—esophageal cancer	0.00267	0.0033	CcSEcCtD
Budesonide—Influenza—Capecitabine—esophageal cancer	0.00265	0.00328	CcSEcCtD
Budesonide—Bronchospasm—Capecitabine—esophageal cancer	0.0026	0.00322	CcSEcCtD
Budesonide—Immune system disorder—Cisplatin—esophageal cancer	0.0026	0.00321	CcSEcCtD
Budesonide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00259	0.0178	CbGpPWpGaD
Budesonide—Mediastinal disorder—Cisplatin—esophageal cancer	0.00259	0.00321	CcSEcCtD
Budesonide—Sweating increased—Capecitabine—esophageal cancer	0.00258	0.00319	CcSEcCtD
Budesonide—Bronchitis—Capecitabine—esophageal cancer	0.00255	0.00315	CcSEcCtD
Budesonide—Alopecia—Cisplatin—esophageal cancer	0.00254	0.00314	CcSEcCtD
Budesonide—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00251	0.0173	CbGpPWpGaD
Budesonide—Malnutrition—Cisplatin—esophageal cancer	0.0025	0.0031	CcSEcCtD
Budesonide—Dysuria—Capecitabine—esophageal cancer	0.00248	0.00306	CcSEcCtD
Budesonide—Flatulence—Cisplatin—esophageal cancer	0.00247	0.00305	CcSEcCtD
Budesonide—Weight increased—Capecitabine—esophageal cancer	0.00241	0.00298	CcSEcCtD
Budesonide—Muscle spasms—Cisplatin—esophageal cancer	0.00241	0.00298	CcSEcCtD
Budesonide—NR3C1—Endoderm Differentiation—SOX2—esophageal cancer	0.0024	0.0165	CbGpPWpGaD
Budesonide—Infestation NOS—Capecitabine—esophageal cancer	0.00236	0.00292	CcSEcCtD
Budesonide—Infestation—Capecitabine—esophageal cancer	0.00236	0.00292	CcSEcCtD
Budesonide—Vision blurred—Cisplatin—esophageal cancer	0.00236	0.00292	CcSEcCtD
Budesonide—Tremor—Cisplatin—esophageal cancer	0.00234	0.0029	CcSEcCtD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX3—esophageal cancer	0.00234	0.0161	CbGpPWpGaD
Budesonide—Ill-defined disorder—Cisplatin—esophageal cancer	0.00232	0.00287	CcSEcCtD
Budesonide—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00231	0.0159	CbGpPWpGaD
Budesonide—Anaemia—Cisplatin—esophageal cancer	0.00231	0.00286	CcSEcCtD
Budesonide—Conjunctivitis—Capecitabine—esophageal cancer	0.00229	0.00284	CcSEcCtD
Budesonide—Urinary tract infection—Capecitabine—esophageal cancer	0.00229	0.00284	CcSEcCtD
Budesonide—Malaise—Cisplatin—esophageal cancer	0.00226	0.00279	CcSEcCtD
Budesonide—Haematuria—Capecitabine—esophageal cancer	0.00225	0.00278	CcSEcCtD
Budesonide—Epistaxis—Capecitabine—esophageal cancer	0.00223	0.00275	CcSEcCtD
Budesonide—Irritability—Methotrexate—esophageal cancer	0.00218	0.00269	CcSEcCtD
Budesonide—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00218	0.0149	CbGpPWpGaD
Budesonide—Prednisolone—CYP2A6—esophageal cancer	0.00217	0.0471	CrCbGaD
Budesonide—Mood swings—Methotrexate—esophageal cancer	0.00216	0.00267	CcSEcCtD
Budesonide—NR3C1—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.00215	0.0148	CbGpPWpGaD
Budesonide—Myalgia—Cisplatin—esophageal cancer	0.00213	0.00264	CcSEcCtD
Budesonide—Haemoglobin—Capecitabine—esophageal cancer	0.00213	0.00264	CcSEcCtD
Budesonide—Rhinitis—Capecitabine—esophageal cancer	0.00212	0.00263	CcSEcCtD
Budesonide—Anxiety—Cisplatin—esophageal cancer	0.00212	0.00263	CcSEcCtD
Budesonide—Haemorrhage—Capecitabine—esophageal cancer	0.00212	0.00262	CcSEcCtD
Budesonide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00212	0.00262	CcSEcCtD
Budesonide—Discomfort—Cisplatin—esophageal cancer	0.0021	0.0026	CcSEcCtD
Budesonide—Pharyngitis—Capecitabine—esophageal cancer	0.0021	0.0026	CcSEcCtD
Budesonide—Urinary tract disorder—Capecitabine—esophageal cancer	0.00209	0.00259	CcSEcCtD
Budesonide—Oedema peripheral—Capecitabine—esophageal cancer	0.00209	0.00258	CcSEcCtD
Budesonide—Connective tissue disorder—Capecitabine—esophageal cancer	0.00208	0.00258	CcSEcCtD
Budesonide—Urethral disorder—Capecitabine—esophageal cancer	0.00208	0.00257	CcSEcCtD
Budesonide—Breast disorder—Methotrexate—esophageal cancer	0.00206	0.00255	CcSEcCtD
Budesonide—Anaphylactic shock—Cisplatin—esophageal cancer	0.00204	0.00253	CcSEcCtD
Budesonide—Visual impairment—Capecitabine—esophageal cancer	0.00204	0.00253	CcSEcCtD
Budesonide—Infection—Cisplatin—esophageal cancer	0.00203	0.00251	CcSEcCtD
Budesonide—Betamethasone—CYP19A1—esophageal cancer	0.00202	0.0439	CrCbGaD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—SFN—esophageal cancer	0.002	0.0137	CbGpPWpGaD
Budesonide—Nervous system disorder—Cisplatin—esophageal cancer	0.002	0.00248	CcSEcCtD
Budesonide—Tachycardia—Cisplatin—esophageal cancer	0.00199	0.00247	CcSEcCtD
Budesonide—Skin disorder—Cisplatin—esophageal cancer	0.00198	0.00245	CcSEcCtD
Budesonide—Eye disorder—Capecitabine—esophageal cancer	0.00198	0.00245	CcSEcCtD
Budesonide—Hyperhidrosis—Cisplatin—esophageal cancer	0.00197	0.00244	CcSEcCtD
Budesonide—Cardiac disorder—Capecitabine—esophageal cancer	0.00197	0.00243	CcSEcCtD
Budesonide—Flushing—Capecitabine—esophageal cancer	0.00197	0.00243	CcSEcCtD
Budesonide—Anorexia—Cisplatin—esophageal cancer	0.00195	0.00241	CcSEcCtD
Budesonide—Angiopathy—Capecitabine—esophageal cancer	0.00192	0.00238	CcSEcCtD
Budesonide—Immune system disorder—Capecitabine—esophageal cancer	0.00191	0.00237	CcSEcCtD
Budesonide—Mediastinal disorder—Capecitabine—esophageal cancer	0.00191	0.00236	CcSEcCtD
Budesonide—Dexamethasone—NOS2—esophageal cancer	0.00189	0.0409	CrCbGaD
Budesonide—Alopecia—Capecitabine—esophageal cancer	0.00187	0.00232	CcSEcCtD
Budesonide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00186	0.0023	CcSEcCtD
Budesonide—Mental disorder—Capecitabine—esophageal cancer	0.00186	0.0023	CcSEcCtD
Budesonide—Malnutrition—Capecitabine—esophageal cancer	0.00184	0.00228	CcSEcCtD
Budesonide—Dysuria—Methotrexate—esophageal cancer	0.00184	0.00228	CcSEcCtD
Budesonide—Paraesthesia—Cisplatin—esophageal cancer	0.00183	0.00227	CcSEcCtD
Budesonide—Dyspnoea—Cisplatin—esophageal cancer	0.00182	0.00225	CcSEcCtD
Budesonide—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00182	0.0125	CbGpPWpGaD
Budesonide—Flatulence—Capecitabine—esophageal cancer	0.00182	0.00225	CcSEcCtD
Budesonide—Dysgeusia—Capecitabine—esophageal cancer	0.00181	0.00223	CcSEcCtD
Budesonide—Back pain—Capecitabine—esophageal cancer	0.00178	0.00221	CcSEcCtD
Budesonide—Decreased appetite—Cisplatin—esophageal cancer	0.00178	0.0022	CcSEcCtD
Budesonide—Muscle spasms—Capecitabine—esophageal cancer	0.00177	0.00219	CcSEcCtD
Budesonide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00176	0.00218	CcSEcCtD
Budesonide—Infestation NOS—Methotrexate—esophageal cancer	0.00176	0.00217	CcSEcCtD
Budesonide—Infestation—Methotrexate—esophageal cancer	0.00176	0.00217	CcSEcCtD
Budesonide—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00175	0.012	CbGpPWpGaD
Budesonide—Pain—Cisplatin—esophageal cancer	0.00175	0.00216	CcSEcCtD
Budesonide—Vision blurred—Capecitabine—esophageal cancer	0.00174	0.00215	CcSEcCtD
Budesonide—Tremor—Capecitabine—esophageal cancer	0.00173	0.00214	CcSEcCtD
Budesonide—NR3C1—Adipogenesis—CYP26A1—esophageal cancer	0.00173	0.0118	CbGpPWpGaD
Budesonide—Ill-defined disorder—Capecitabine—esophageal cancer	0.00171	0.00212	CcSEcCtD
Budesonide—Conjunctivitis—Methotrexate—esophageal cancer	0.00171	0.00211	CcSEcCtD
Budesonide—Anaemia—Capecitabine—esophageal cancer	0.0017	0.00211	CcSEcCtD
Budesonide—Feeling abnormal—Cisplatin—esophageal cancer	0.00168	0.00208	CcSEcCtD
Budesonide—Haematuria—Methotrexate—esophageal cancer	0.00168	0.00207	CcSEcCtD
Budesonide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00167	0.0115	CbGpPWpGaD
Budesonide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00167	0.0115	CbGpPWpGaD
Budesonide—Malaise—Capecitabine—esophageal cancer	0.00166	0.00206	CcSEcCtD
Budesonide—Epistaxis—Methotrexate—esophageal cancer	0.00166	0.00205	CcSEcCtD
Budesonide—Vertigo—Capecitabine—esophageal cancer	0.00166	0.00205	CcSEcCtD
Budesonide—Syncope—Capecitabine—esophageal cancer	0.00165	0.00205	CcSEcCtD
Budesonide—Palpitations—Capecitabine—esophageal cancer	0.00163	0.00202	CcSEcCtD
Budesonide—Loss of consciousness—Capecitabine—esophageal cancer	0.00162	0.00201	CcSEcCtD
Budesonide—Body temperature increased—Cisplatin—esophageal cancer	0.00161	0.002	CcSEcCtD
Budesonide—Cough—Capecitabine—esophageal cancer	0.00161	0.00199	CcSEcCtD
Budesonide—Dexamethasone—CYP1B1—esophageal cancer	0.0016	0.0348	CrCbGaD
Budesonide—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.0016	0.011	CbGpPWpGaD
Budesonide—Hypertension—Capecitabine—esophageal cancer	0.00159	0.00197	CcSEcCtD
Budesonide—Haemoglobin—Methotrexate—esophageal cancer	0.00159	0.00196	CcSEcCtD
Budesonide—Haemorrhage—Methotrexate—esophageal cancer	0.00158	0.00195	CcSEcCtD
Budesonide—Chest pain—Capecitabine—esophageal cancer	0.00157	0.00194	CcSEcCtD
Budesonide—Arthralgia—Capecitabine—esophageal cancer	0.00157	0.00194	CcSEcCtD
Budesonide—Myalgia—Capecitabine—esophageal cancer	0.00157	0.00194	CcSEcCtD
Budesonide—Pharyngitis—Methotrexate—esophageal cancer	0.00157	0.00194	CcSEcCtD
Budesonide—Anxiety—Capecitabine—esophageal cancer	0.00156	0.00194	CcSEcCtD
Budesonide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00156	0.0107	CbGpPWpGaD
Budesonide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00156	0.00193	CcSEcCtD
Budesonide—Urinary tract disorder—Methotrexate—esophageal cancer	0.00156	0.00193	CcSEcCtD
Budesonide—Discomfort—Capecitabine—esophageal cancer	0.00155	0.00192	CcSEcCtD
Budesonide—Urethral disorder—Methotrexate—esophageal cancer	0.00155	0.00191	CcSEcCtD
Budesonide—Dry mouth—Capecitabine—esophageal cancer	0.00154	0.0019	CcSEcCtD
Budesonide—Visual impairment—Methotrexate—esophageal cancer	0.00152	0.00188	CcSEcCtD
Budesonide—Confusional state—Capecitabine—esophageal cancer	0.00152	0.00188	CcSEcCtD
Budesonide—Hypersensitivity—Cisplatin—esophageal cancer	0.0015	0.00186	CcSEcCtD
Budesonide—Infection—Capecitabine—esophageal cancer	0.0015	0.00185	CcSEcCtD
Budesonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—esophageal cancer	0.00149	0.0102	CbGpPWpGaD
Budesonide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00149	0.0102	CbGpPWpGaD
Budesonide—Shock—Capecitabine—esophageal cancer	0.00148	0.00183	CcSEcCtD
Budesonide—Nervous system disorder—Capecitabine—esophageal cancer	0.00148	0.00183	CcSEcCtD
Budesonide—Eye disorder—Methotrexate—esophageal cancer	0.00147	0.00182	CcSEcCtD
Budesonide—Tachycardia—Capecitabine—esophageal cancer	0.00147	0.00182	CcSEcCtD
Budesonide—Asthenia—Cisplatin—esophageal cancer	0.00147	0.00181	CcSEcCtD
Budesonide—Cardiac disorder—Methotrexate—esophageal cancer	0.00146	0.00181	CcSEcCtD
Budesonide—Skin disorder—Capecitabine—esophageal cancer	0.00146	0.00181	CcSEcCtD
Budesonide—Hyperhidrosis—Capecitabine—esophageal cancer	0.00146	0.0018	CcSEcCtD
Budesonide—Anorexia—Capecitabine—esophageal cancer	0.00143	0.00178	CcSEcCtD
Budesonide—Angiopathy—Methotrexate—esophageal cancer	0.00143	0.00177	CcSEcCtD
Budesonide—Immune system disorder—Methotrexate—esophageal cancer	0.00142	0.00176	CcSEcCtD
Budesonide—Mediastinal disorder—Methotrexate—esophageal cancer	0.00142	0.00176	CcSEcCtD
Budesonide—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00141	0.00968	CbGpPWpGaD
Budesonide—Diarrhoea—Cisplatin—esophageal cancer	0.0014	0.00173	CcSEcCtD
Budesonide—Alopecia—Methotrexate—esophageal cancer	0.00139	0.00172	CcSEcCtD
Budesonide—NR3C1—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.00139	0.00952	CbGpPWpGaD
Budesonide—Mental disorder—Methotrexate—esophageal cancer	0.00138	0.00171	CcSEcCtD
Budesonide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00138	0.00944	CbGpPWpGaD
Budesonide—Malnutrition—Methotrexate—esophageal cancer	0.00137	0.0017	CcSEcCtD
Budesonide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00137	0.0017	CcSEcCtD
Budesonide—NR3C1—Endoderm Differentiation—SMAD4—esophageal cancer	0.00137	0.00941	CbGpPWpGaD
Budesonide—Insomnia—Capecitabine—esophageal cancer	0.00136	0.00168	CcSEcCtD
Budesonide—Paraesthesia—Capecitabine—esophageal cancer	0.00135	0.00167	CcSEcCtD
Budesonide—Dysgeusia—Methotrexate—esophageal cancer	0.00134	0.00166	CcSEcCtD
Budesonide—Dyspnoea—Capecitabine—esophageal cancer	0.00134	0.00166	CcSEcCtD
Budesonide—NR3C1—Circadian Clock—HIF1A—esophageal cancer	0.00133	0.00912	CbGpPWpGaD
Budesonide—Back pain—Methotrexate—esophageal cancer	0.00133	0.00164	CcSEcCtD
Budesonide—Dyspepsia—Capecitabine—esophageal cancer	0.00133	0.00164	CcSEcCtD
Budesonide—Decreased appetite—Capecitabine—esophageal cancer	0.00131	0.00162	CcSEcCtD
Budesonide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.0013	0.00161	CcSEcCtD
Budesonide—Vomiting—Cisplatin—esophageal cancer	0.0013	0.00161	CcSEcCtD
Budesonide—Fatigue—Capecitabine—esophageal cancer	0.0013	0.00161	CcSEcCtD
Budesonide—Vision blurred—Methotrexate—esophageal cancer	0.00129	0.0016	CcSEcCtD
Budesonide—Rash—Cisplatin—esophageal cancer	0.00129	0.00159	CcSEcCtD
Budesonide—Constipation—Capecitabine—esophageal cancer	0.00129	0.00159	CcSEcCtD
Budesonide—Pain—Capecitabine—esophageal cancer	0.00129	0.00159	CcSEcCtD
Budesonide—Dermatitis—Cisplatin—esophageal cancer	0.00129	0.00159	CcSEcCtD
Budesonide—NR3C1—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.00128	0.00878	CbGpPWpGaD
Budesonide—Ill-defined disorder—Methotrexate—esophageal cancer	0.00127	0.00158	CcSEcCtD
Budesonide—Anaemia—Methotrexate—esophageal cancer	0.00127	0.00157	CcSEcCtD
Budesonide—Dexamethasone—ABCC2—esophageal cancer	0.00125	0.0272	CrCbGaD
Budesonide—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00125	0.00858	CbGpPWpGaD
Budesonide—Feeling abnormal—Capecitabine—esophageal cancer	0.00124	0.00153	CcSEcCtD
Budesonide—Malaise—Methotrexate—esophageal cancer	0.00124	0.00153	CcSEcCtD
Budesonide—NR3C1—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.00124	0.00848	CbGpPWpGaD
Budesonide—Dexamethasone—CYP2A6—esophageal cancer	0.00124	0.0268	CrCbGaD
Budesonide—Vertigo—Methotrexate—esophageal cancer	0.00123	0.00153	CcSEcCtD
Budesonide—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00123	0.00152	CcSEcCtD
Budesonide—Nausea—Cisplatin—esophageal cancer	0.00121	0.0015	CcSEcCtD
Budesonide—Cough—Methotrexate—esophageal cancer	0.0012	0.00148	CcSEcCtD
Budesonide—Urticaria—Capecitabine—esophageal cancer	0.0012	0.00148	CcSEcCtD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—SMAD4—esophageal cancer	0.00119	0.00818	CbGpPWpGaD
Budesonide—Abdominal pain—Capecitabine—esophageal cancer	0.00119	0.00147	CcSEcCtD
Budesonide—Body temperature increased—Capecitabine—esophageal cancer	0.00119	0.00147	CcSEcCtD
Budesonide—Dexamethasone—CYP19A1—esophageal cancer	0.00118	0.0255	CrCbGaD
Budesonide—Chest pain—Methotrexate—esophageal cancer	0.00117	0.00145	CcSEcCtD
Budesonide—Arthralgia—Methotrexate—esophageal cancer	0.00117	0.00145	CcSEcCtD
Budesonide—Myalgia—Methotrexate—esophageal cancer	0.00117	0.00145	CcSEcCtD
Budesonide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00116	0.00144	CcSEcCtD
Budesonide—Discomfort—Methotrexate—esophageal cancer	0.00116	0.00143	CcSEcCtD
Budesonide—Methylprednisolone—ABCB1—esophageal cancer	0.00115	0.0249	CrCbGaD
Budesonide—Triamcinolone—PTGS2—esophageal cancer	0.00114	0.0247	CrCbGaD
Budesonide—Confusional state—Methotrexate—esophageal cancer	0.00113	0.0014	CcSEcCtD
Budesonide—Anaphylactic shock—Methotrexate—esophageal cancer	0.00112	0.00139	CcSEcCtD
Budesonide—NR3C1—Regulation of Androgen receptor activity—CREBBP—esophageal cancer	0.00112	0.00768	CbGpPWpGaD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—BAX—esophageal cancer	0.00112	0.00766	CbGpPWpGaD
Budesonide—Infection—Methotrexate—esophageal cancer	0.00111	0.00138	CcSEcCtD
Budesonide—Hypersensitivity—Capecitabine—esophageal cancer	0.00111	0.00137	CcSEcCtD
Budesonide—Nervous system disorder—Methotrexate—esophageal cancer	0.0011	0.00136	CcSEcCtD
Budesonide—NR3C1—AP-1 transcription factor network—HIF1A—esophageal cancer	0.0011	0.00752	CbGpPWpGaD
Budesonide—Skin disorder—Methotrexate—esophageal cancer	0.00109	0.00135	CcSEcCtD
Budesonide—NR3C1—Circadian Clock—CREBBP—esophageal cancer	0.00109	0.00745	CbGpPWpGaD
Budesonide—Hyperhidrosis—Methotrexate—esophageal cancer	0.00108	0.00134	CcSEcCtD
Budesonide—Asthenia—Capecitabine—esophageal cancer	0.00108	0.00134	CcSEcCtD
Budesonide—Anorexia—Methotrexate—esophageal cancer	0.00107	0.00132	CcSEcCtD
Budesonide—Pruritus—Capecitabine—esophageal cancer	0.00107	0.00132	CcSEcCtD
Budesonide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00106	0.00728	CbGpPWpGaD
Budesonide—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00105	0.00724	CbGpPWpGaD
Budesonide—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00105	0.00718	CbGpPWpGaD
Budesonide—Diarrhoea—Capecitabine—esophageal cancer	0.00103	0.00127	CcSEcCtD
Budesonide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00102	0.00126	CcSEcCtD
Budesonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—esophageal cancer	0.00102	0.00697	CbGpPWpGaD
Budesonide—Insomnia—Methotrexate—esophageal cancer	0.00101	0.00125	CcSEcCtD
Budesonide—NR3C1—Endoderm Differentiation—NOTCH1—esophageal cancer	0.00101	0.00694	CbGpPWpGaD
Budesonide—Paraesthesia—Methotrexate—esophageal cancer	0.00101	0.00125	CcSEcCtD
Budesonide—Dyspnoea—Methotrexate—esophageal cancer	0.000999	0.00124	CcSEcCtD
Budesonide—Somnolence—Methotrexate—esophageal cancer	0.000996	0.00123	CcSEcCtD
Budesonide—Dizziness—Capecitabine—esophageal cancer	0.000995	0.00123	CcSEcCtD
Budesonide—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.000994	0.00682	CbGpPWpGaD
Budesonide—Dyspepsia—Methotrexate—esophageal cancer	0.000986	0.00122	CcSEcCtD
Budesonide—Decreased appetite—Methotrexate—esophageal cancer	0.000974	0.00121	CcSEcCtD
Budesonide—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000968	0.0012	CcSEcCtD
Budesonide—Fatigue—Methotrexate—esophageal cancer	0.000966	0.0012	CcSEcCtD
Budesonide—NR3C1—SIDS Susceptibility Pathways—SST—esophageal cancer	0.000962	0.0066	CbGpPWpGaD
Budesonide—Pain—Methotrexate—esophageal cancer	0.000958	0.00119	CcSEcCtD
Budesonide—Vomiting—Capecitabine—esophageal cancer	0.000957	0.00118	CcSEcCtD
Budesonide—Rash—Capecitabine—esophageal cancer	0.000949	0.00117	CcSEcCtD
Budesonide—Dermatitis—Capecitabine—esophageal cancer	0.000948	0.00117	CcSEcCtD
Budesonide—Headache—Capecitabine—esophageal cancer	0.000943	0.00117	CcSEcCtD
Budesonide—Betamethasone—PTGS2—esophageal cancer	0.00093	0.0202	CrCbGaD
Budesonide—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000925	0.00635	CbGpPWpGaD
Budesonide—Feeling abnormal—Methotrexate—esophageal cancer	0.000923	0.00114	CcSEcCtD
Budesonide—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000916	0.00113	CcSEcCtD
Budesonide—Nausea—Capecitabine—esophageal cancer	0.000894	0.00111	CcSEcCtD
Budesonide—Urticaria—Methotrexate—esophageal cancer	0.00089	0.0011	CcSEcCtD
Budesonide—Body temperature increased—Methotrexate—esophageal cancer	0.000886	0.0011	CcSEcCtD
Budesonide—Abdominal pain—Methotrexate—esophageal cancer	0.000886	0.0011	CcSEcCtD
Budesonide—Prednisone—ABCB1—esophageal cancer	0.000876	0.019	CrCbGaD
Budesonide—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00086	0.0059	CbGpPWpGaD
Budesonide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.00083	0.00569	CbGpPWpGaD
Budesonide—Hypersensitivity—Methotrexate—esophageal cancer	0.000826	0.00102	CcSEcCtD
Budesonide—Prednisolone—ABCB1—esophageal cancer	0.000807	0.0175	CrCbGaD
Budesonide—Asthenia—Methotrexate—esophageal cancer	0.000804	0.000995	CcSEcCtD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—esophageal cancer	0.000797	0.00547	CbGpPWpGaD
Budesonide—Pruritus—Methotrexate—esophageal cancer	0.000793	0.000981	CcSEcCtD
Budesonide—Betamethasone—ABCB1—esophageal cancer	0.000791	0.0172	CrCbGaD
Budesonide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00079	0.00542	CbGpPWpGaD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—esophageal cancer	0.000789	0.00541	CbGpPWpGaD
Budesonide—NR3C1—AP-1 transcription factor network—CDKN2A—esophageal cancer	0.000784	0.00538	CbGpPWpGaD
Budesonide—Diarrhoea—Methotrexate—esophageal cancer	0.000767	0.000949	CcSEcCtD
Budesonide—NR3C1—Regulation of Androgen receptor activity—EP300—esophageal cancer	0.000762	0.00523	CbGpPWpGaD
Budesonide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000756	0.00519	CbGpPWpGaD
Budesonide—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000754	0.00517	CbGpPWpGaD
Budesonide—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000746	0.00512	CbGpPWpGaD
Budesonide—Dizziness—Methotrexate—esophageal cancer	0.000741	0.000917	CcSEcCtD
Budesonide—NR3C1—Circadian Clock—EP300—esophageal cancer	0.00074	0.00508	CbGpPWpGaD
Budesonide—Vomiting—Methotrexate—esophageal cancer	0.000713	0.000882	CcSEcCtD
Budesonide—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000709	0.00486	CbGpPWpGaD
Budesonide—Rash—Methotrexate—esophageal cancer	0.000707	0.000874	CcSEcCtD
Budesonide—Dermatitis—Methotrexate—esophageal cancer	0.000706	0.000873	CcSEcCtD
Budesonide—Headache—Methotrexate—esophageal cancer	0.000702	0.000869	CcSEcCtD
Budesonide—NR3C1—Adipogenesis—HIF1A—esophageal cancer	0.000668	0.00458	CbGpPWpGaD
Budesonide—Nausea—Methotrexate—esophageal cancer	0.000666	0.000824	CcSEcCtD
Budesonide—NR3C1—AP-1 transcription factor network—CCND1—esophageal cancer	0.000663	0.00455	CbGpPWpGaD
Budesonide—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000652	0.00447	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—NR1I2—esophageal cancer	0.00063	0.00433	CbGpPWpGaD
Budesonide—Hydrocortisone—ABCB1—esophageal cancer	0.000617	0.0134	CrCbGaD
Budesonide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000613	0.0042	CbGpPWpGaD
Budesonide—NR3C1—AP-1 transcription factor network—EP300—esophageal cancer	0.00061	0.00419	CbGpPWpGaD
Budesonide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000609	0.00418	CbGpPWpGaD
Budesonide—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000601	0.00413	CbGpPWpGaD
Budesonide—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000581	0.00399	CbGpPWpGaD
Budesonide—NR3C1—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000577	0.00396	CbGpPWpGaD
Budesonide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000573	0.00393	CbGpPWpGaD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—esophageal cancer	0.00057	0.00391	CbGpPWpGaD
Budesonide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000565	0.00388	CbGpPWpGaD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—esophageal cancer	0.000565	0.00388	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.00056	0.00384	CbGpPWpGaD
Budesonide—NR3C1—Adipogenesis—RB1—esophageal cancer	0.000544	0.00373	CbGpPWpGaD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—esophageal cancer	0.000543	0.00372	CbGpPWpGaD
Budesonide—Dexamethasone—PTGS2—esophageal cancer	0.000541	0.0117	CrCbGaD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—EP300—esophageal cancer	0.000537	0.00369	CbGpPWpGaD
Budesonide—NR3C1—AP-1 transcription factor network—MYC—esophageal cancer	0.000531	0.00365	CbGpPWpGaD
Budesonide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000494	0.00339	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000491	0.00337	CbGpPWpGaD
Budesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—esophageal cancer	0.000473	0.00324	CbGpPWpGaD
Budesonide—NR3C1—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000472	0.00324	CbGpPWpGaD
Budesonide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000464	0.00319	CbGpPWpGaD
Budesonide—Dexamethasone—ABCB1—esophageal cancer	0.00046	0.00999	CrCbGaD
Budesonide—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000457	0.00313	CbGpPWpGaD
Budesonide—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000451	0.00309	CbGpPWpGaD
Budesonide—NR3C1—AP-1 transcription factor network—TP53—esophageal cancer	0.000436	0.00299	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000425	0.00291	CbGpPWpGaD
Budesonide—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000419	0.00287	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—SMG6—esophageal cancer	0.000401	0.00275	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.000396	0.00272	CbGpPWpGaD
Budesonide—NR3C1—Adipogenesis—CDKN1A—esophageal cancer	0.000391	0.00268	CbGpPWpGaD
Budesonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—esophageal cancer	0.000385	0.00264	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.000355	0.00244	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000346	0.00238	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000329	0.00226	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000325	0.00223	CbGpPWpGaD
Budesonide—NR3C1—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000321	0.0022	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000309	0.00212	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—NR1I2—esophageal cancer	0.000304	0.00208	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—SMAD4—esophageal cancer	0.000298	0.00205	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000262	0.0018	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—HIST1H2BM—esophageal cancer	0.00026	0.00179	CbGpPWpGaD
Budesonide—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000259	0.00178	CbGpPWpGaD
Budesonide—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000247	0.00169	CbGpPWpGaD
Budesonide—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000243	0.00167	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.00022	0.00151	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—PSME2—esophageal cancer	0.000202	0.00139	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—PSME1—esophageal cancer	0.000202	0.00139	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—CREBBP—esophageal cancer	0.000199	0.00137	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—NOTCH3—esophageal cancer	0.000191	0.00131	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—NOTCH2—esophageal cancer	0.000171	0.00117	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—SMAD4—esophageal cancer	0.000144	0.000985	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000133	0.000909	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000133	0.000909	CbGpPWpGaD
Budesonide—NR3C1—Generic Transcription Pathway—MYC—esophageal cancer	0.000118	0.000812	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—CA1—esophageal cancer	0.000113	0.000773	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000113	0.000773	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—NOTCH1—esophageal cancer	0.000106	0.000726	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—CA2—esophageal cancer	0.000103	0.000707	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—CREBBP—esophageal cancer	9.59e-05	0.000658	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—PLCE1—esophageal cancer	9.58e-05	0.000658	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—ADH7—esophageal cancer	9.58e-05	0.000658	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—ADH1B—esophageal cancer	8.4e-05	0.000577	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—TYMP—esophageal cancer	8.03e-05	0.000551	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—CYP26A1—esophageal cancer	7.81e-05	0.000536	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—ALOX15—esophageal cancer	7.61e-05	0.000522	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—TPI1—esophageal cancer	7.26e-05	0.000498	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—GSTO1—esophageal cancer	7.26e-05	0.000498	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—ALDOB—esophageal cancer	6.96e-05	0.000478	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—GAPDH—esophageal cancer	6.7e-05	0.00046	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—CRABP1—esophageal cancer	6.64e-05	0.000456	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—GNG7—esophageal cancer	6.32e-05	0.000434	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—ALDH2—esophageal cancer	5.92e-05	0.000406	CbGpPWpGaD
Budesonide—NR3C1—Gene Expression—MYC—esophageal cancer	5.69e-05	0.000391	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—GSTT1—esophageal cancer	5.63e-05	0.000386	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—CYP2A6—esophageal cancer	5.57e-05	0.000382	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—ENO1—esophageal cancer	5.28e-05	0.000362	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—PTGS1—esophageal cancer	5.28e-05	0.000362	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—PSME2—esophageal cancer	5.2e-05	0.000357	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—PSME1—esophageal cancer	5.2e-05	0.000357	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.49e-05	0.000308	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.22e-05	0.000289	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.85e-05	0.000264	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.69e-05	0.000254	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.47e-05	0.000169	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—NOS3—esophageal cancer	2.21e-05	0.000152	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.02e-05	0.000139	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—EP300—esophageal cancer	1.68e-05	0.000115	CbGpPWpGaD
Budesonide—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.24e-05	8.54e-05	CbGpPWpGaD
